Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation Validates Eyenovia’s proprietary Optejet® dispensing platform World-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe becomes first to incorporate Mydcombi into his daily practice NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) […]
Making It Possible
In-Office Pupil Dilation
Estimated US Market Size: $250M
Estimated US Market Size $7.7B
*Outlicensed in Asia
Estimated US Market Size $5.0B
*Outlicensed in USA, Canada, Asia
We are creating transformative therapies currently being studied for use in progressive myopia, presbyopia, and mydriasis. We believe that our innovation in ophthalmic delivery will change the way eyecare professionals and patients view eye medications. Eyenovia strives to create ophthalmic drug delivery technologies that are more effective, safer, and smarter than traditional eyedroppers. Our Optejet® dispenser is designed to deliver minimal amounts of medication to the eye, horizontally, while maintaining similar efficacy to traditional eyedropper treatment. The Optejet® has the potential to come equipped with Bluetooth capability, to help track patient compliance and adherence more easily.
We envision the Optejet®’s technology being utilized for additional applications and drug therapies. Reduction in systemic exposure and toxicity with the Optejet®’s microdosing, compared to a traditional eyedropper, could mean the dispenser may have a better tolerability and safety profile than existing topical treatments. For therapies where adherence is vital to treatment success, the Optejet® may assist with patient compliance.
Optejet® has not been approved or cleared by the FDA for any use and is not commercially available in the United States or in any jurisdiction.